-
1.发明申请PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE 审中-公开用于预防或治疗非酒精性脂肪肝疾病的药物组合物公开(公告)号：US20150056223A1
公开(公告)日：2015-02-26
申请号：US14383954
申请日：2013-03-08
发明人： Se Young Lim , Sung Hee Park , Ryoung Ae Shin , In Young Choi , Se Chang Kwon
IPC分类号： A61K47/48 , C07K14/605 , C07K16/18 , A61K38/26 , A61K39/395
CPC分类号： A61K47/48215 , A61K38/26 , A61K39/3955 , A61K47/60 , A61K47/6883 , A61K2039/505 , C07K14/605 , C07K16/18 , C07K2317/41 , C07K2317/75 , C07K2317/94
摘要： The present invention relates to a pharmaceutical composition for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD), including a conjugate prepared by covalently linking an insulinotropic peptide, a non-peptidyl polymer and an immunoglobulin Fc region. The composition of the present invention maintains the in-vivo activity of the peptide at a relatively high level, and remarkably increases the blood half-life, thereby preventing triglyceride accumulation which is a typical feature of non-alcoholic fatty liver disease. Ultimately, it can be desirably employed for the prevention and treatment of non-alcoholic fatty liver disease.
摘要翻译： 本发明涉及用于预防和治疗非酒精性脂肪肝疾病（NAFLD）的药物组合物，其包括通过共价连接促胰岛素肽，非肽基聚合物和免疫球蛋白Fc区而制备的缀合物。 本发明的组合物将肽的体内活性维持在较高的水平，显着增加血液半衰期，从而防止作为非酒精性脂肪性肝病的典型特征的甘油三酯积聚。 最终，可以理想地用于预防和治疗非酒精性脂肪性肝病。
-
公开(公告)号：US11872283B2
公开(公告)日：2024-01-16
申请号：US16506717
申请日：2019-07-09
发明人： Sung Youb Jung , Dae Jin Kim , Sung Hee Park , Young Eun Woo , In Young Choi , Se Chang Kwon
CPC分类号： A61K45/06 , A61K38/26 , A61K47/60 , A61K47/68 , A61K47/6801 , A61K47/6811 , A61K47/6889 , C07K14/575 , A61K38/00 , C07K2319/30
摘要： The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.
-
公开(公告)号：US10363320B2
公开(公告)日：2019-07-30
申请号：US15636160
申请日：2017-06-28
发明人： Sung Youb Jung , Dae Jin Kim , Sung Hee Park , Young Eun Woo , In Young Choi , Se Chang Kwon
摘要： The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.
-
公开(公告)号：US20140357843A1
公开(公告)日：2014-12-04
申请号：US14369616
申请日：2012-12-28
发明人： Euh Lim Oh , Yong Ho Huh , Sang Youn Hwang , In Young Choi , Sung Youb Jung , Se Chang Kwon
CPC分类号： C07K16/283 , A61K38/26 , A61K47/6849 , C07K16/00 , C07K2317/52 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30
摘要： The present invention relates to immunoglobulin Fc variants having an increased binding affinity for FcRn, which is characterized by including one or more amino acid modifications selected from the group consisting of 307S, 308F, 380S, 380A, 428L, 429K, 430S, 433K and 434S (this numbering is according to the EU index) in the constant region of a native immunoglobulin Fc fragment. Owing to the high binding affinity for FcRn, the immunoglobulin Fc variants according to the present invention show more prolonged in vivo half-life, and thus can be used for the preparation of a long-acting formulation of protein drugs.
摘要翻译： 本发明涉及对FcRn具有增加的结合亲和力的免疫球蛋白Fc变体，其特征在于包括一个或多个选自307S，308F，380S，380A，428L，429K，430S，433K和434S的氨基酸修饰 （该编号根据EU指数）在天然免疫球蛋白Fc片段的恒定区中。 由于对FcRn的高结合亲和力，根据本发明的免疫球蛋白Fc变体显示更长的体内半衰期，因此可用于制备蛋白质药物的长效制剂。
-
-
-
搜索结果
4 条记录 (耗时 0.01 秒)
